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Abstract
Background: This study aimed to investigate the efficacy of prophylactic amifostine in reducing the risk of severe 
radiation colitis in cancer patients receiving radical radiotherapy to the pelvis.
Methods: Patients with pelvic tumours referred for radical radiotherapy who consented participation in this trial, were 
randomly assigned to receive daily amifostine (A) (subcutaneously, 500 mg flat dose) before radiotherapy or 
radiotherapy alone (R). Sigmoidoscopy and blinded biopsies were scheduled to conduct prior to initiation and 
following completion of radiotherapy and again 6 to 9 months later. Radiation colitis was assessed by clinical, 
endoscopic and histolopathological criteria.
Results: A total 44 patients were enrolled in this trial, the majority with rectal (20 patients) and cervical cancer (12 
patients) and were assigned 23 in R arm and 21 in the A arm. In total 119 sigmoidoscopies were performed and 18 
patients (18/44, 40.9%) were diagnosed with radiation colitis (15 grade 1 and 2, and 3 grade 3 and 4). Of them, 6 
patients belonged to the A group (6/21, 28.6%) and 12 to the R group (12/23, 52.2%). Acute and grade IV radiation 
colitis was only developed in four patients (17.4%) in the R group. Amifostine side effects were mild. Amifostine treated 
patients were less likely to develop histologically detectable mucosal lesions, which indicate protection from acute 
mucosal injury.
Conclusions: Amifostine given subcutaneously can lower the risk of acute severe radiation colitis in patients who 
receive radical radiotherapy to pelvic tumors.
Background
External beam radiotherapy to the pelvis is related to the
development of radiation colitis which is a consequence
of radiation-induced mucosal and bowel wall injury.
Although in recent years radiation techniques have
improved with regard to best dosimetric accuracy, radia-
tion toxicity remains a significant clinical problem result-
ing in treatment delays, increased patient hospitalisation
rates and remarkable short and long-term morbidity
[1,2].
Prevention of radiation-induced bowel injury has been
the focus of several studies. Among regimens so far inves-
tigated one of the best-known radioprotectors is consid-
ered to be amifostine. Amifostine is an organic
thiophosphate cytoprotective agent known chemically as
2-[(3-aminopropyl) amino] ethanethiol dihydrogen phos-
phate (ester) [3].
The ability of amifostine to protect normal tissues is
attributed to the higher capillary alkaline phosphatase
activity, higher pH and better vascularity of normal tis-
sues compared to tumour tissue, resulting in a more rapid
generation of the active thiol metabolite and thereby
detoxifying the reactive metabolites and scavenging reac-
tive oxygen species generated by radiation [4].
Randomised clinical trials in patients with pelvic malig-
nancies demonstrated that prophylactic amifostine
reduces radiation-induced toxicity in lower gastrointesti-
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nal tract, pelvic skin and perineal area without compro-
mising the anti-tumor effect [5]. However, results were
mainly based on clinical assessments while concomitant
endoscopic and histopathologic features of the radiation-
induced damage in bowel mucosa were not described [6-
10].
The aim of this study was to assess the efficacy of sub-
cutaneous amifostine in preventing radiation colitis in
patients irradiated for pelvic neoplasms, by combining
clinical, endoscopic and histopathologic data.
Methods
Study and Patients
This randomised phase II exploratory clinical trial was
activated in May 2001 and conducted in an Academic
Hospital [University General Hospital]. The procedures
followed were in accordance with the Helsinki Declara-
tion (1964, amended in 1975, 1983, 1989, 1996 and 2000)
of the World Medical Association. Institutional review
boards and the ethics committee of our University Hospi-
tal approved the trial protocol with and patient informed
consent. Patients with pelvic malignancies were consid-
ered for participation into this trial if they fulfilled a list of
eligibility criteria [see below] and signed an informed
consent.
Enrolled patients were randomly assigned to receive
daily amifostine (subcutaneously, 500 mg flat dose)
before radiotherapy (A) or radiotherapy alone (R). Sig-
moidoscopy and blinded biopsies were scheduled for all
patients prior to initiation of treatment and twice follow-
ing completion of radiotherapy.
Study endpoints
The primary study endpoint was to determine the effi-
cacy of amifostine in preventing radiation-induced colitis
(RC) by using combined clinical, endoscopic and histo-
pathologic data from patients irradiated to the pelvis.
The secondary endpoints of the study were the assess-
ment of agreement between clinical, endoscopic and his-
topathologic data during radiotherapy and post-
radiotherapy period and the evaluation of amifostine-
related toxicity.
Eligibility criteria
The study enrolled patients with primary pelvic or meta-
static to the pelvis malignancies who were referred for
adjuvant, radical or palliative radiotherapy but not for re-
irradiation. All patients recruited in the study were older
than 18 years, had a World Health Organization (WHO)
performance status 0-2 and a life expectancy of more
than 6 months. Pregnant or lactating women, patients
with severe infections or severe psychiatric or neurologic
illnesses were excluded. Patients with decreased hemato-
logic reserves, with major organ failure, severe electrolyte
or metabolic abnormalities were also excluded. In
patients with haemoglobin levels below 11 g/dl before
radiotherapy, subcutaneous erythropoietin was adminis-
tered. Patients with hypertension controlled with medi-
cation were eligible for amifostine administration.
Patients with asymptomatic low blood pressure were
included. Patients with symptomatic hypotension were
excluded. Patients with a previous history of chronic coli-
tis, non-specific proctitis, ulcerative colitis, diverticular
disease or those who were on treatment with non-steroi-
dal anti-inflammatory drugs were excluded.
Basic assessments and randomisation
Pre-radiotherapy assessment included a detailed medical
history, complete physical examination, peripheral blood
count and biochemistry, electrocardiogram, chest X-ray,
computed tomography or magnetic resonance imaging of
the abdomen and pelvis, bone scintigraphy -when indi-
cated- and flexible sigmoidoscopy with bowel biopsies
from areas included within the radiation fields.
All patients were randomised 1:1 to receive subcutane-
ous amifostine (Ethyol, Schering Plough S.A) immediately
before each fraction of radiotherapy (Group A) or radio-
therapy alone (Group R).
Radiotherapy modifications
All patients but one received radical or postoperative
external beam radiotherapy by a linear accelerator (6
MV) and one patient was treated using a Cobalt-60 unit.
Four parallel opposed fields - anteroposterior, posteroan-
terior and two laterals- were applied (box technique). The
median daily radiation dose was 1.9 Gy. All fields were
treated every day (5 fractions/week) and the mean num-
ber of fractions per patient was 28 (range 23-36 frac-
tions).
Reasons for treatment discontinuation were disease
progression during treatment, severe or life threatening
radiation toxicity, patient decision to stop treatment,
poor patient compliance or systemic reactions due to
amifostine use. All patients with any sign of severe toxic-
ity not responding to standard measures discontinued
radiotherapy.
Amifostine administration
Patients randomised to the A group (Amifostine plus
Radiotherapy) were adequately hydrated and pre-treated
with antiemetics 1-2 hours prior to the administration of
amifostine. Amifostine was given subcutaneously at a flat
dose of 500 mg. Amifostine injection was repeated daily
(5 days/week), 20-30 minutes before radiotherapy.
Endoscopic surveillance and follow-up
All patients in both groups (A and R) were planned to
undergo three endoscopies (sigmoidoscopies, up to theKatsanos et al. Journal of Experimental & Clinical Cancer Research 2010, 29:68
http://www.jeccr.com/content/29/1/68
Page 3 of 9
splenic flexure). The first sigmoidoscopy would be per-
formed before the initiation of radiotherapy, the second
after the completion of radiotherapy (approximately 40
days after the first) and the third at least six months after
the end of radiotherapy.
Diagnosis of radiation colitis (RC) was based on
patients' symptoms, laboratory tests, endoscopic and his-
tological findings. Biopsy specimens from each patient
consisted of at least 3 samples of large bowel mucosa,
taken blindly from the region included in the radiation
field every 10 cm, or from areas that appeared to be
affected (at least one sample), as well as from normal-
appearing mucosa (at least one sample). The same gastro-
enterologist, who was blinded to the patient treatment
arm, assessed in each endoscopy the extent and the
degree of colonic mucosal damage.
Radiation toxicity to the bowel was assessed using the
RTOG/EORTC late radiation morbidity scale for large
intestine as the only validated currently available scale
[11]. Patients diagnosed with radiation colitis (RC) were
divided into early (acute) onset RC (symptoms of RC
within 6 months after completion of radiotherapy) and
late onset RC (RC occurring later than 6 months after the
end of radiotherapy).
Assessment of response to radiotherapy
We monitored patients during daily radiotherapy ses-
sions and also during post-radiotherapy follow up.
Response assessment to radiotherapy was assessed by
means of computed tomography and endoscopies. In
addition, WHO performance status, bowel overall func-
tion and daily movements, blood pressure and body
weight were also monitored.
Evaluation of toxicity
During radiotherapy and on a weekly basis, clinical exam-
ination and signs of toxicity were recorded according to
Common Toxicity Criteria (CTC, version 2.0). Amifostine
toxicity was also assessed by the CTC criteria. After the
end of radiotherapy and every three months for the first
two years and then every six months for the next years,
clinical examination and evaluation of toxicity were also
planned.
Histopathological study
Bowel mucosa biopsies were fixed in 4% buffered forma-
lin, embedded in paraffin and cut in 5 μm sections. For
histological evaluation the sections were stained with the
standard haematoxylin-eosin (H&E) stain. Furthermore,
immunostaining was performed by the labeled straptavi-
din-avidin-biotin method (LSAB Kit, Dako SA, Glostrup,
Denmark) using the monoclonal antibody directed
against active caspase 3 (dilution 1:500; clone C92-605,
Pharmigen, San Diego, CA), as previously described [12].
Evaluation of Haematoxylin-eosin (H&E) staining
Since there are no general and precisely defined criteria
for histologic diagnosis and grading of radiation colitis
our histologic reports were based on relevant studies and
textbooks [13,14]. According to these colitis lesions were
graded as absent (-), mild (+) and moderate to severe (++/
+++). Histologic features of colitis included presence of
increased inflammatory infiltration of the lamina propria
(estimation of proportion of neutrophils, eosinophils,
lymphocytes and plasma cells, as well as the presence of
muciphages-foamy cells), presence of erosions or ulcers,
absence of viable crypts and presence of cryptitis (inflam-
matory cells permeating the crypt epithelium and
destroying crypts) and crypt abscesses (cellular cell irreg-
ularities, cytoplasmic vacuolation, nuclear abnormalities,
increased apoptotic bodies), architectural crypt distor-
tion (crypt branching and shortening, crypt disarray-
slight distortion with widening, atrophy) presence of
fibrosis of the lamina propria, vascular changes (telangi-
ectasia, endothelial degeneration, platelet thrombi forma-
tion).
Evaluation of immunostaining
The number of active caspase 3 positive epithelial cells,
within the surface epithelium as well as within the crypts,
was recorded by using the ×40 objective lens. Since the
tissue contained in the biopsies was limited, the whole
biopsy area was evaluated in all cases. The apoptotic
index (AI) was expressed as the number of active caspase
3-positive epithelial cells per 10 high power fields. Tissue
sections were examined independently by two of the
authors who were blinded to the treatment group and to
the sigmoidoscopy findings. Discrepancies were resolved
at the discussion microscope.
Statistical Analysis
The sample size in the study was set for logistic reasons to
40 patients; minimum 20 patients per treatment arm.
Continuous variables were described as means ± SD
when were normally distributed or as median with maxi-
mal and minimal range for observations not normally dis-
tributed. Comparison between groups was performed
using ANOVA and Student's t-test. X2 analysis was used
when comparing frequencies. A p value < 0.05 (two-
tailed) was considered to be significant. For all calcula-
tions we used the SPSS 12.0 working package (SPSS Inc.,
Chicago, IL).
Results
A total of 44 patients (23 females, 21 males) with a
median age of 63 years (range 35-79 years) were enrolled
in this trial. Of them, 20 had rectal cancer, 12 cervical
cancer, 5 prostate cancer, 3 urinary bladder cancer, 2
endometrial cancer and 2 sarcomas of the pelvis. Twenty-Katsanos et al. Journal of Experimental & Clinical Cancer Research 2010, 29:68
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one patients were randomised to receive amifostine prior
to radiotherapy (group A) and 23 patients received only
radiotherapy (group R).
Radical radiotherapy was administered in 24 patients.
Adjuvant radiotherapy was administered in 20 patients
(15 with rectal cancer, 3 with cervical cancer, and 2 with
pelvic sarcoma). Patient characteristics are summarized
in Table 1.
Radiotherapy dose
The mean total radiation dose was 50.4 Gy for the ami-
fostine plus radiation group (A) and 50.2 Gy for the radio-
therapy alone group (R). Nine females with cervical
cancer received additional brachytherapy with median
total dose of 24 Gy. There was no significant difference
between the total RT dose in patients diagnosed with or
without radiation colitis (50.3 Gy in both groups, p > 0.5).
Radiotherapy delays and amifostine toxicity
All patients completed radiotherapy as planned. Two
patients in the A group (1 patient with cervical and 1
patient with prostate cancer) temporarily interrupted
radiotherapy on weeks 2 and 3 respectively due to side
effects unrelated to amifostine (neutropenia grade 3).
Radiotherapy was restarted in both of them 3 weeks later
and was completed uneventfully.
No dose adjustment of amifostine was made for toxic-
ity. Amifostine-related side effects occurred in 4 out of 21
patients (19%) and were mild. Two patients developed
local erythema and pruritus at the site of amifostine sub-
cutaneous injection (grade 1) and 2 patients had nausea
or/and vomiting grade 1 and 2.
W i t h i n  a  m e d i a n  f o l l o w  u p  t i m e  o f  2 4  m o n t h s ,  o n e
patient with bladder cancer and one patient with rectal
cancer operated due to local relapse after radiotherapy
and 5 patients (5/44 = 11.4%) died. None of deaths was
associated to radiation colitis or amifostine but was solely
attributed to disease progression.
Endoscopic findings
A total of 119 sigmoidoscopies were performed. All
patients had a baseline sigmoidoscopy and at least one
follow-up endoscopy as planned (median 2.7 endoscopies
per patient). There were no significant differences
between the two groups (A vs R) regarding patient age,
time of follow-up or cumulative number of endoscopies
[in detail, 59 vs 62 years of age, 24.5 vs 23.5 months of fol-
low up, 58 vs 61endoscopies].
Eighteen out of 44 patients (40.9%) were diagnosed
with radiation colitis (RC). Of these 18 patients, 6 were in
the A group (6/21 patients = 28.6%) and 12 in the R group
(12/23 patients = 52.2%) [p = 0.29]. The endoscopic find-
Table 1: Demographics and study characteristics in cancer patients receiving external pelvic radiotherapy with or without 
amifostine prophylaxis.
Total A* R**
No of patients treated 44 21 23
Gender:
Female 23 15 8
Male 21 5 16
Age:
Median (range) 63(34-79) 59 62
Tumor types:
Rectal 20 7 13
Cervical 12 8 4
Prostate 5 2 3
Bladder 3 1 3
Endometrial 2 2 -
Sarcoma 2 - 2
Mean radiation dose (Gy): 50.4 50.2
*A = Amifostine
**R = Radiotherapy aloneKatsanos et al. Journal of Experimental & Clinical Cancer Research 2010, 29:68
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ings and grading of RC are listed in Table 2. Sigmoido-
scopic findings ranged from minor signs of inflammation
to more prominent signs of bowel mucosa injury (Figures
1A-B).
Four patients (17.4%) in the R group developed acute
colitis and two of them required hospitalization. By con-
trast none of the patients in the A+R group developed
acute colitis [17.4% vs 0%, p = 0.05].
Histopathological findings
Haematoxylin-eosin staining
Based on the histologic features noted with the haema-
toxylin-eosin stain, cases were allocated to one of the fol-
lowing four groups: 1) no changes, when no changes were
noted in bowel mucosa; 2) acute injury, characterized by
the presence of ulceration and diffuse infiltration by poly-
morphonuclear leucocytes as well as eosinophil granulo-
cytes, the near absence of viable crypts, the presence of
cryptitis and other damage in the surviving epithelium,
endothelial degeneration and platelet thrombi (Figure
2A); 3) early regenerative changes, characterized by
absence of ulceration, considerably less acute inflamma-
tion but noteworthy infiltration by eosinophil granulo-
c y t e s ,  a s  w e l l  a s  p l a s m a  c e l l s ,  l y m p h o c y t e s  a n d
m u c i p h a g e s ,  p r e s e n c e  o f  v i a b l e  c r y p t s  w i t h  d i s a r r a y ,
absence of cryptitis or acute epithelial damage, some
endothelial degeneration and telangiectasia as well as
mild fibrosis of the lamina propria (Figure 2B) and 4) late
regenerative changes, characterized by minimal (if any)
acute inflammation, mild diffuse infiltration by plama
cells and lymphocytes, consistent presence of muci-
phages, architectural crypt distortion, with reduced
crypts, crypt branching and shortening as well as moder-
ate/severe fibrosis of the lamina propria (Figure 2C). The
presence of eosinophils in the lamina propria, particu-
larly on the acute and early regenerative phase was noted
in almost all specimens. However, in contrast with the
radiation colitis induced by pre-operative irradiation no
"eosinophil crypt abscesses" was observed, even in acute
injury.
In a minority of our patients an acute mucosal injury,
was diagnosed histologically. More specifically, of all
patients administered amifostine, none exhibited acute
mucosal injury, regardless of the biopsy timing (early or
late). Furthermore, of the eight patients receiving amifos-
tine and undergoing early biopsies, four (50%) exhibited
early regenerative changes; two (25%) late regenerative
changes and two (25%) had no abnormal histological
findings. Of the fourteen patients receiving amifostine
and undergoing late biopsies, three (21.4%) showed early
regenerative changes, nine (64.3%) late regenerative
changes and two (14.3%) had no abnormal histological
findings. Acute mucosal injury was histologically charac-
terized in three patients who did not receive amifostine;
in two out of the seven (28.6%) patients with early biop-
sies and one out of the fifteen patients with late biopsies
(6.7%).
Furthermore, in arm R, early biopsies early regenerative
changes in two (28.6%) and late regenerative changes in
two (28.6%) patients. In the same group, late biopsies
revealed early regenerative changes in five (33.3%) and
late regenerative changes in eight (53.3%) patients. The
differences between the groups were not statistically sig-
nificant.
Table 2: Endoscopic findings and grading of radiation colitis in cancer patients receiving external pelvic radiotherapy with 
or without amifostine prophylaxis.
A + R (N = 21) R (N = 23)
Endoscopically rated colitis Acute Late Acute Late
G r a d e  1 ---2
G r a d e  2 -626
Grade 3 - 1 1 -
Grade 4 - - 1 -
Totals (%) -
(0%)+
7
(28,6%)
4
(17,4%)+
8
(34,8%)
*A = Amifostine
**R = Radiotherapy
+ p = 0.05Katsanos et al. Journal of Experimental & Clinical Cancer Research 2010, 29:68
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Immunohistochemistry
The apoptotic index (AI) was calculated in bowel speci-
mens from both groups (A and R) and was analysed in
relation to the timing of radiotherapy (AI1 = biopsy
before the initiation of radiotherapy, AI2 = biopsy after
the completion of radiotherapy and AP3 = biopsy at least
six months after the end of radiotherapy). In the A group
of patients the AI1, AI2 and AI3 were [mean ± SD] 1.0 ±
0.6, 1.1 ± 0.7 and 1.4 ± 0.8 and in the R group of patients
the AI1, AI2, AI3 were 1.0 ± 0.6, 1.3 ± 1.0 and 0.9 ± 0.3
respectively [Figure 3]. No significant differences were
observed for the AI1, AI2 and AI3 between the two
patient groups.
Concordance of endoscopic and histopathological findings
The concordance between histologically defined radia-
tion colitis and endoscopic findings was rather poor with
endoscopy findings underestimating bowel mucosal
injury. Characteristically, in patients with endoscopically
mild to moderate colitis (EORTC/RTOG grade 1-2) the
corresponding large bowel mucosa histologic changes
were disproportionally pronounced.
Radiation colitis management
All cases of RC were manageable. In cases of mild to
moderate RC (grade I and II), patients were treated on
ou t pa t ie n t  bas is.  F o r m or e seve r e  sym pt om s  (gr a de III
and IV) hospitalisation was necessary for 10-15 days.
Mild and moderate RC cases were treated with corticos-
teroid and mesalamine enemas administered twice daily
for a period of 10-20 days according to clinical response.
Discussion
This is the first randomized explanatory study that
assessed amifostine efficacy in patients undergoing exter-
nal beam irradiation for pelvic malignancies by means of
combining clinical, endoscopic and histological data.
Patients on prophylactic subcutaneous amifostine
developed less acute RC compared to patients who did
not receive amifostine prophylaxis, yet the small size of
this study did not allow us to reach to statistically signifi-
cant findings. However, acute RC and grade IV radiation
colitis did not occur in the amifostine arm but only in
four patients (17.4%) who did not receive amifostine pro-
phylaxis (arm R). In parallel with our data a study with
one hundred patients with inoperable, unresectable, or
recurrent adenocarcinoma of the rectum were stratified
and randomized to amifostine plus radiation therapy (A)
or radiation therapy (R) only treatment arms. According
to this study, the administration of amifostine concomi-
tant to radiation for advanced rectal cancer, was reported
to significantly reduce acute and late pelvic radiation tox-
icity [15,16].
Furthermore, several studies have also shown a radia-
tion protective function of amifostine to perineal, skin,
bladder, and bowel mucosa in patients irradiated for pel-
vic area malignancies [17-31]. Overall, there is accumu-
lating data demonstrating that amifostine may protect
from acute and late onset colitis and well-designed short
and long-term protection protocols may prove of great
importance.
Reporting and assessing toxicity is important in all
oncological trials. This study confirmed what others have
already shown that subcutaneous amifostine at 500 mg is
well tolerated [5].
Pathologists are familiar with delayed colitis, which
develops months to years after pelvic radiotherapy for
rectal, gynecologic, or bladder cancers but grading acute
radiation injury to bowel mucosa represents an unad-
dressed issue. Differential diagnosis of acute or late onset
radiation colitis is broad. It is noteworthy that the pres-
ence of nuclear abnormalities in acute radiation colitis
may mimic epithelial dysplasia in ulcerative colitis [32].
Figure 1 A. Congested rectal mucosa with diffuse erythema in a 
case of grade I radiation colitis (RTOG/EORTC late radiation mor-
bidity scale for large intestine). B. Ulcerated rectal mucosa with dif-
fuse erythema, mucous and intermittent bleeding in a case of grade II 
radiation colitis (RTOG/EORTC late radiation morbidity scale for large 
intestine).Katsanos et al. Journal of Experimental & Clinical Cancer Research 2010, 29:68
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In contrast to reported observation of eosinophilic
crypt abscesses in irradiated bowel mucosa in cancer
patients who received pre-operative irradiation, such
findings were not observed in our patients, even in cases
with an acute RC. Another study [18] had systematically
characterized acute radiation colitis in patients treated
with short-term preoperative radiotherapy for rectal can-
cer. However, due to the nature of the material examined
(surgical resection specimens) in that study no correla-
tion with endoscopical findings was made. In addition,
findings analyzed were representing areas from peritu-
moral colonic mucosa, which conceivably could be
affected by the adjacent tumor. Other investigators have
addressed interesting issues regarding RC pathogenesis,
besides morphology, and have reported that transient
aberrant expression of P-cadherin may be associated with
proctitis [33].
In an interesting study [34], also supportive of the pro-
phylactic role of amifostine, radiation-induced acute rec-
tal toxicity was evaluated by using three different toxicity
scales: WHO scale, EORTC/RTOG toxicity criteria, and a
modified toxicity scale. In the present study we have used
precisely defined criteria for grading of acute and also of
late radiation colitis, based on published reports and text-
books, and thus we were able to semiquantitavely com-
pare histologic changes and endoscopy between groups.
From the histologic data it is evident that patients receiv-
ing amifostine are less likely to develop histologically
detectable mucosal changes Furthermore, the adminis-
tration of amifostine appears to protect patients from
acute mucosal injury. We have further extended our his-
topathologic study by examining the immunohistochemi-
cal expression of active caspase-3. Immunohistochemical
expression of active caspace 3 in cells is a valuable means
of detection of apoptosis induced by a wide variety of
apoptotic signal [12].
We detected active caspase-3 in all biopsy specimens,
early or late, with or without amifostine, even in pre-radi-
ation biopsies. However, significant differences between
treatent arms were not detected. This is probably due, at
least in part, to drop-out of the epithelium in the acute
injury phase, were the apoptotic index (AI) should be the
highest.
It is of interest that in both patient groups in this study
the correlation of histopathologically defined phases of
radiation-induced colitis and endoscopic findings was
poor. Consistent with these data is another study [35],
which failed to show a correlation between histopatho-
logical findings and clinical status of patients with colon
cancer treated pre-operatively with irradiation. The
observa tions of this study indica te that acute radiation
colitis may remain clinically silent and resolve spontane-
Figure 2 Histopathological findings of radiation-induced colitis. A. Acute injury, characterized by ulceration, absence of viable crypts, diffuse in-
filtration by polymorphonuclear leucocytes, and prominent capillaries lined by plump endothelial cells (H + E × 400). B. Early regenerative changes, 
characterized by absence of ulceration, considerably less acute inflammation, infiltration by plasma cells and lymphocytes, presence of viable crypts 
with disarray, absence of cryptitis or acute epithelial damage (H+E × 400). C. Late regenerative changes, characterized by absence of acute inflamma-
tion, mild diffuse infiltration by plama cells and lymphocytes, architectural crypt distortion, with reduced crypts, crypt branching and shortening as 
well as moderate/severe fibrosis of the lamina propria (H + E × 400).
Figure 3 Immunohistochemical expression of active caspase 3 in 
apoptotic epithelial cells.Katsanos et al. Journal of Experimental & Clinical Cancer Research 2010, 29:68
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ously within a few weeks after irradiation. Given the
increasing acceptance of short-term preoperative irradia-
tion protocols for rectal cancer, pathologists should be
aware of the rather characteristic histopathologic find-
ings of acute radiation colitis and avoid unnecessary con-
cern of clinicians.
Conclusions
In conclusion, this is one of the first studies to assess the
efficacy of prophylactic amifostine efficacy by using clini-
cal, endoscopic and histologic assessment in patients
receiving radical radiotherapy to pelvic tumors. Subcuta-
neous amifostine prophylactic was safe and seemed to
provide protection to the development of severe and
acute radiation colitis. Larger studies and longer follow
up is needed to confirm and evaluate the long-term pro-
tective function of amifostine.
The poor concordance of endoscopic and histologic
findings undercores the need for a global assessment of
radiation-induced bowel injury by clinical, endoscopic,
and histological means.
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